Literature DB >> 26323976

Successful immunoadsorption of life-threatening bleeding in factor VIII inhibitor disease, but no long-term remission with anti-CD20 treatment.

Florian Grahammer1, Karl-Georg Fischer1.   

Abstract

A 62-year-old man and a 64-year-old woman presented to our institution with acquired haemophilia A. They both developed life-threatening bleeding. Immunoadsorption using protein A columns was used to rapidly lower factor VIII inhibitor levels. Immunosuppression with steroids and the anti-CD20 antibody, rituximab, was instituted. Yet their effects were either partial or complicated by an early relapse. Repetitive cyclophosphamide administration led to a sustained immunological response. While immunoadsorption appears effective and safe to lower factor VIII inhibitor levels, it seems that further preferably randomised controlled trials are needed to establish the value of rituximab versus the standard immunosuppressive regime comprising cyclophosphamide. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26323976      PMCID: PMC4693128          DOI: 10.1136/bcr-2015-210034

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses.

Authors:  Karl-Georg Fischer; Barbara Deschler; Michael Lübbert
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

2.  Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept.

Authors:  Heike Zeitler; Gudrun Ulrich-Merzenich; Lothar Hess; Eligius Konsek; Christoph Unkrig; Peter Walger; Hans Vetter; Hans-Hermann Brackmann
Journal:  Blood       Date:  2004-11-12       Impact factor: 22.113

3.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

Review 4.  Acquired haemophilia.

Authors:  C R Hay
Journal:  Baillieres Clin Haematol       Date:  1998-06

Review 5.  Acquired hemophilia A: a concise review.

Authors:  Massimo Franchini; Giorgio Gandini; Tiziana Di Paolantonio; Guglielmo Mariani
Journal:  Am J Hematol       Date:  2005-09       Impact factor: 10.047

6.  Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus.

Authors:  S Schulman; P Langevitz; A Livneh; U Mortinowitz; U Seligsohn; D Varon
Journal:  Thromb Haemost       Date:  1996-09       Impact factor: 5.249

7.  Rituximab in the treatment of acquired factor VIII inhibitors.

Authors:  Adrian Wiestner; Hearn J Cho; Adam S Asch; Mary Ann Michelis; Jack A Zeller; Ellinor I B Peerschke; Babette B Weksler; Geraldine P Schechter
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

8.  Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus.

Authors:  T E Lafferty; J B Smith; S J Schuster; R J DeHoratius
Journal:  Arthritis Rheum       Date:  1997-04

Review 9.  Rituximab in the treatment of adult acquired hemophilia A: a systematic review.

Authors:  Massimo Franchini
Journal:  Crit Rev Oncol Hematol       Date:  2007-01-19       Impact factor: 6.312

10.  Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII.

Authors:  John Freedman; Margaret L Rand; Olive Russell; Carole Davis; Patricia L Cheatley; Victor Blanchette; M Bernadette Garvey
Journal:  Transfusion       Date:  2003-11       Impact factor: 3.157

View more
  1 in total

Review 1.  Rituximab for eradicating inhibitors in people with acquired haemophilia A.

Authors:  Tracey Remmington; Sherie Smith
Journal:  Cochrane Database Syst Rev       Date:  2021-08-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.